Overview

Detailed Summary

Par Drugs and Chemicals Limited manufactures Active Pharma Ingredients (APIs) and fine chemicals for both domestic and international markets, operating two facilities in Gujarat, India.
The company focuses on a diversified portfolio with 12 APIs and 6 fine chemicals, expanding its market reach to approximately 16 countries.
In 2021, Par Drugs expanded its production capacity by introducing a new manufacturing block, demonstrating potential growth in its existing product segments.
The Bhavnagar facility is certified by food & drugs control administration, reflecting the company's commitment to maintaining high-quality production standards.
Key customers include reputable names like Pfizer Limited and United Phosphorus Limited, indicating strong industry partnerships and reputation.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 113 Cr
Volatility: Moderate Risk
P/E Ratio: 8.1
Industry P/E: 33.2
PEG Ratio: 0.6
P/B Ratio: 1.1
52W High: 122.43
52W Low: 78.05

Sales CAGR

1Y: 5.57%
3Y: 10.15%
5Y: 15.22%
10Y: —

Profit CAGR

1Y: -7.86%
3Y: 13.18%
5Y: 22.90%
10Y: —

ROE

TTM: 9.10%
3Y: 15.32%
5Y: 16.31%
10Y: —

ROCE

TTM: 12.39%
3Y: 19.80%
5Y: 20.80%
10Y: —

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
GODAVARI		92.00	116 Cr	31.43	1.75	0.00	12.65	11.11	2.27
PAR		91.30	112 Cr	8.06	1.05	0.00	9.10	12.39	10.91
ACCPL		73.50	110 Cr	12.07	2.43	0.00	19.50	25.71	15.37
CONCORD		86.00	110 Cr	192.25	2.38	0.00	1.67	6.00	0.83
DENISCHEM		78.80	110 Cr	12.56	1.25	1.90	8.16	14.50	7.05
PHARMAID		30.50	109 Cr	-7.86	2.10	0.00	-31.40	-26.43	-15.53
VAISHALI		7.71	105 Cr	-198.15	1.56	0.00	-0.57	1.54	-0.43
Median: 7 Co.	—	78.80	110 Cr	12.07	1.75	0.00	8.16	11.11	2.27

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	26	24	23	23	35	21	22	26	29	29
Expenses	19	19	17	18	23	20	20	22	23	23
Operating Profit	7.37	5.23	6.09	4.24	11	1.42	2.43	3.56	6.07	6.06
OPM %	28.47	21.79	26.69	18.75	32.92	6.64	10.88	13.67	21.18	20.65
Other Income	0.05	0.23	-0.05	0.07	1.02	0.27	0.79	1.84	0.48	1.33
Interest	0.03	0.02	0.05	0.02	0.03	0.01	0.02	0.02	0.05	0.01
Depreciation	0.85	0.87	0.89	0.90	0.91	0.91	0.92	0.90	0.94	0.93
Profit Before Tax	6.54	4.57	5.11	3.39	11	0.77	2.28	4.48	5.55	6.44
Tax %	25.23	25.16	27.20	25.07	25.15	24.68	27.63	25.67	25.59	25.47
Net Profit	4.89	3.42	3.72	2.53	8.60	0.58	1.65	3.33	4.13	4.80
EPS in Rs	3.97	2.78	3.02	2.06	6.99	0.47	1.34	2.70	3.36	3.90

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	49	42	46	56	69	85	96	96	113	104
Expenses	40	34	38	46	45	59	78	73	81	86
Operating Profit	8.54	8.03	8.20	9.45	24	26	18	23	32	19
OPM %	17.52	18.94	17.71	16.92	35.22	30.68	19.02	23.86	28.15	18.02
Other Income	0.04	0.04	0.09	0.10	2.18	0.18	0.24	0.24	2.15	3.92
Interest	2.50	2.33	1.96	0.79	0.64	0.45	0.13	0.11	0.08	0.08
Depreciation	2.82	3.14	3.04	2.76	2.82	3.28	3.23	3.44	3.65	3.64
Profit Before Tax	3.27	2.60	3.29	5.99	15	13	15	20	18	19
Tax %	46.28	41.35	23.72	20.48	21.15	27.47	24.84	25.70	25.47	25.55
Net Profit	1.75	1.52	2.51	4.76	12	9.21	11	15	13	14
EPS in Rs	—	—	—	—	—	7.57	9.21	11.78	10.86	11.30
Dividend Payout %	0.00	0.00	0.00	32.26	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	2.70	2.70	4.48	6.15	6.15	12	12	12	12
Reserves	11	13	25	34	46	48	59	73	87
Borrowings	25	23	10	4.62	7.64	0.00	0.00	0.00	0.00
Other Liabilities	17	15	12	15	17	19	18	16	20
Total Liabilities	56	54	51	60	76	79	89	102	119
Fixed Assets	42	39	36	34	30	34	38	41	39
CWIP	0.00	0.00	0.00	0.74	4.52	0.25	0.25	0.03	0.00
Investments	0.06	0.06	0.06	0.06	0.01	0.01	0.01	0.01	25
Other Assets	14	15	15	25	42	44	50	60	55
Total Assets	56	54	51	60	76	79	89	102	119

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	9.39	4.65	3.36	7.69	12	7.62	13	20	16
Cash from Investing Activity	-1.70	-0.60	-0.25	-1.46	0.05	-3.02	-7.34	-5.84	-25
Cash from Financing Activity	-8.60	-4.00	-3.14	1.11	1.65	-9.55	-0.00	0.00	0.00
Net Cash Flow	-0.91	0.05	-0.03	7.35	14	-4.96	6.04	14	-9.08

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	74.21%	74.21%	74.21%	74.21%	74.21%	74.21%	73.37%	73.37%	73.37%	73.37%	73.37%	73.41%
FIIs	0.00%	0.00%	0.00%	0.07%	0.06%	0.32%	0.09%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	25.79%	25.79%	25.79%	25.73%	25.68%	25.47%	26.54%	26.63%	26.63%	26.63%	26.63%	26.59%
Total Shareholders	5,585	5,686	5,902	7,020	7,403	8,022	8,757	17,199	15,472	14,887	14,280	13,761

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY23

Investor Presentation

Q4 FY23

Investor Presentation

Q3 FY23

Available on Pro Plan